These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 27987579)

  • 1. Response and acquired resistance to crizotinib in Chinese patients with lung adenocarcinomas harboring MET Exon 14 splicing alternations.
    Dong HJ; Li P; Wu CL; Zhou XY; Lu HJ; Zhou T
    Lung Cancer; 2016 Dec; 102():118-121. PubMed ID: 27987579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
    Jorge SE; Schulman S; Freed JA; VanderLaan PA; Rangachari D; Kobayashi SS; Huberman MS; Costa DB
    Lung Cancer; 2015 Dec; 90(3):369-74. PubMed ID: 26791794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired resistance to crizotinib in advanced lung adenocarcinoma with MET exon 14 skipping.
    Zhang Y; Yin J; Peng F
    Lung Cancer; 2017 Nov; 113():69-71. PubMed ID: 29110851
    [No Abstract]   [Full Text] [Related]  

  • 4. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
    Paik PK; Drilon A; Fan PD; Yu H; Rekhtman N; Ginsberg MS; Borsu L; Schultz N; Berger MF; Rudin CM; Ladanyi M
    Cancer Discov; 2015 Aug; 5(8):842-9. PubMed ID: 25971939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
    Mahjoubi L; Gazzah A; Besse B; Lacroix L; Soria JC
    Invest New Drugs; 2016 Jun; 34(3):397-8. PubMed ID: 26892698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
    J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature.
    Mengoli MC; Barbieri F; Bertolini F; Tiseo M; Rossi G
    Lung Cancer; 2016 Mar; 93():55-8. PubMed ID: 26898615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
    Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
    Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
    Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
    Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation.
    Jenkins RW; Oxnard GR; Elkin S; Sullivan EK; Carter JL; Barbie DA
    Clin Lung Cancer; 2015 Sep; 16(5):e101-4. PubMed ID: 25769807
    [No Abstract]   [Full Text] [Related]  

  • 11. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
    Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
    J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon 14 Splicing Mutations.
    Zhang Y; Wang W; Wang Y; Xu Y; Tian Y; Huang M; Lu Y
    J Thorac Oncol; 2016 May; 11(5):e59-e62. PubMed ID: 26724472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination therapy of erlotinib/crizotinib in a lung adenocarcinoma patient with primary EGFR mutation plus secondary MET amplification and a novel acquired crizotinib-resistant mutation MET G1108C.
    Li YQ; Song SS; Jiang SH; Zhang XY
    Ann Oncol; 2017 Oct; 28(10):2622-2624. PubMed ID: 28961830
    [No Abstract]   [Full Text] [Related]  

  • 14. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification.
    Du J; Wu X; Tong X; Wang X; Wei J; Yang Y; Chang Z; Mao Y; Shao YW; Liu B
    Oncotarget; 2017 Apr; 8(16):26281-26287. PubMed ID: 28460431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
    Wang Y; Chen Z; Han X; Li J; Guo H; Shi J
    Oncologist; 2021 Mar; 26(3):178-181. PubMed ID: 33000474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor.
    Benderra MA; Aspeslagh S; Postel-Vinay S; Bigot L; De Baere T; Loriot Y; Lacroix L; Massard C; Vassal G; André F; Soria JC
    J Thorac Oncol; 2016 Feb; 11(2):e21-3. PubMed ID: 26845121
    [No Abstract]   [Full Text] [Related]  

  • 18. Detection of Crizotinib-Sensitive Lung Adenocarcinomas With MET, ALK, and ROS1 Genomic Alterations via Comprehensive Genomic Profiling.
    Le X; Freed JA; VanderLaan PA; Huberman MS; Rangachari D; Jorge SE; Lucena-Araujo AR; Kobayashi SS; Balasubramanian S; He J; Chudnovsky Y; Miller VA; Ali SM; Costa DB
    Clin Lung Cancer; 2015 Sep; 16(5):e105-9. PubMed ID: 25922291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lazarus-Type Response to Crizotinib in a Patient with Poor Performance Status and Advanced MET Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma.
    Shea M; Huberman MS; Costa DB
    J Thorac Oncol; 2016 Jul; 11(7):e81-2. PubMed ID: 26845194
    [No Abstract]   [Full Text] [Related]  

  • 20. Lung adenocarcinoma harboring concomitant SPTBN1-ALK fusion, c-Met overexpression, and HER-2 amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy.
    Gu FF; Zhang Y; Liu YY; Hong XH; Liang JY; Tong F; Yang JS; Liu L
    J Hematol Oncol; 2016 Aug; 9(1):66. PubMed ID: 27496196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.